Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study

Current Medical Research and Opinion

Volumn 30, Issue 2, 2014, Pages 163-175

  Stenlöf, Kaj ^a   Cefalu, William T ^b,c   Kim, Kyoung Ah ^d   Jodar, Esteban ^e   Alba, Maria ^f   Edwards, Robert ^f   Tong, Cindy ^f   Canovatchel, William ^f   Meininger, Gary ^f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Dongguk University Ilsan Hospital   (South Korea)

^e HOSPITAL QUIRÓN   (Spain)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Body weight reduction; Canagliflozin; Glycemic control; Phase 3 study; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; CANAGLIFLOZIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITAGLIPTIN; SULFONYLUREA; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; PLACEBO; PYRAZINE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE; TRIACYLGLYCEROL; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; KINESIOTHERAPY; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POLYURIA; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET; DRUG EFFECTS; EXERCISE; METABOLISM; MIDDLE AGED;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIET; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; PYRAZINES; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME; TRIAZOLES; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84893299467     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.850066     Document Type: Article

References (24)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
2. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000
3. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
4. Bode B, Stenlö f K, Sullivan D, et al. Efficacy and safety of canagliflozin in older subjects with type 2 diabetes: A randomized trial. Hosp Pract 2013;41: 72-84
5. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, doubleblind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
6. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
7. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week, randomized trial. Diabetes Care 2013;36:2508-15
8. Stenlö f K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
9. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
10. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013: Published online 19 Jun 2013. doi: 10.1111/dom.12149
11. Lavalle-Gonzalez F, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013: Published online 13 Sep 2013. doi: 10.1007/s00125-013-3039-1
12. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45
13. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-Transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72
14. Polidori D, Sha S, Ghosh A, et al. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozintreated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:E867-71
15. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Obes Res 1998;6:51-209S
16. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-Treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002;25:1033-1
17. ONeil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-36
18. Janssen Research & Development LLC. Endocrinologic and Metabolic Drugs Advisory Committee. January 10, 2013. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-Administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. JNJ-28431754 (Canagliflozin). NDA 204042. Available at: Http:// www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMat erials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UC M334551.pdf [last accessed 8 May 2013]
19. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
20. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:721-8
21. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
22. Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
23. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8
24. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38